2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.
Adam D. Cohen, MD, assistant professor of medicine, director, Myeloma Immunotherapy, University of Pennsylvania, discusses outcomes with ciltacabtagene autoleucel (cilta-cel), as demonstrated in the phase 2 CARTITUDE-2 study (NCT04133636) in patients with multiple myeloma.
CARTITUDE-2 is evaluating the safety and efficacy of cilta-cel in patients with progressive disease following 1 to 3 prior lines of therapy, as well as in those who are lenalidomide (Revlimid) refractory and who have not received prior BCMA-targeting agents.
Data from cohort A showed that the CAR T-cell therapy induced an overall response rate of 95% in the 20 patients enrolled, according to Cohen. Additionally, 75% of patients achieved a complete response (CR) or better with cilta-cel, making the efficacy similar to what had been reported in the phase 1/2 CARTITUDE 1 trial (NCT03548207), Cohen adds.
In cohort A, the median time to response was approximately 1.0 month, and the median time to CR was 1.9 months. The median follow-up was 5.8 months at the time of data cutoff, and no patients had progressed at that time, Cohen explains. All patients are in ongoing remission, although more follow-up is needed to determine the durability of responses and how these data compare with what has been observed in more heavily pretreated patients, Cohen concludes.